Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis.

[1]  W. Ageno,et al.  Single intravenous administration of TB‐402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose‐escalating, randomized, controlled trial , 2011, Journal of thrombosis and haemostasis : JTH.

[2]  M. Makris,et al.  The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies , 2011, International journal of laboratory hematology.

[3]  B. Nemery,et al.  Short‐term exposure to particulate matter induces arterial but not venous thrombosis in healthy mice , 2010, Journal of thrombosis and haemostasis : JTH.

[4]  M. Poncz,et al.  Towards a standardization of the murine tail bleeding model , 2010, Journal of thrombosis and haemostasis : JTH.

[5]  T. Wakefield,et al.  Thrombogenesis with continuous blood flow in the inferior vena cava , 2010, Thrombosis and Haemostasis.

[6]  P. Verhamme,et al.  Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. , 2010, Clinical therapeutics.

[7]  P. Verhamme,et al.  A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons , 2009, Journal of thrombosis and haemostasis : JTH.

[8]  B. Giraudeau,et al.  Influence of source of phospholipids for APTT‐based factor IX assays and potential consequences for the diagnosis of mild haemophilia B , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  C. Legrand,et al.  Hemostatic effects of recombinant DisBa-01, a disintegrin from Bothrops alternatus. , 2008, Frontiers in bioscience : a journal and virtual library.

[10]  D. Quartermain,et al.  Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke , 2007, Neurological research.

[11]  A. Girolami,et al.  Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases , 2006, Journal of Thrombosis and Thrombolysis.

[12]  R. Dwek,et al.  Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody , 2006, Journal of thrombosis and haemostasis : JTH.

[13]  F. Rosendaal,et al.  Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.

[14]  J. Hoogmartens,et al.  Book Reviews : Who Expert Committee on Specifications for Pharmaceutical Preparations. Published by World Health Organisation, 1984. Price: Sw. fr. 6. Paperback. Pp 54. ISBN: 924 120704 3 , 1985, World Health Organization technical report series.

[15]  M. Dewerchin,et al.  Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice , 2004, Journal of thrombosis and haemostasis : JTH.

[16]  K. Svenson,et al.  Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. , 2002, Physiological genomics.

[17]  R. Bertina,et al.  Elevated Factor VIII Levels and the Risk of Thrombosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  G. Broze,et al.  A Tail Vein Bleeding Time Model and Delayed Bleeding in Hemophiliac Mice , 2001, Thrombosis and Haemostasis.

[19]  M. Laffan,et al.  Elevated plasma factor VIII levels--a novel risk factor for venous thromboembolism. , 2001, Clinical laboratory.

[20]  J. Vermylen,et al.  A New Animal Model of Thrombophilia Confirms that High Plasma Factor VIII Levels Are Thrombogenic , 1999, Thrombosis and Haemostasis.

[21]  M F Hoylaerts,et al.  Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.

[22]  O. Ratnoff,et al.  The changing prognosis of classic hemophilia (factor VIII "deficiency"). , 1991, Annals of internal medicine.

[23]  D. Hoppensteadt,et al.  Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins , 1989, Annals of the New York Academy of Sciences.